Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-05-30
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]
2025-03-17
The cost of GLP-1s needs to come way down for benefits to be worth it, study says
While weight-loss drugs like Zepbound (LLY) and Wegovy (NVO) offer significant health benefits, their high costs make them economically inefficient under current U.S. healthcare standards, according t [...]
2025-01-10
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]
2025-03-28
Cheaper Wegovy, 23andMe shutters, and RFK Jr. cuts FDA jobs: Pharma news roundup
Novo Nordisk is expanding its cash-only savings program offering its blockbuster weight-loss drug Wegovy for $499 a month at all U.S. pharmacies. 23andMe has filed for Chapter 11 bankruptcy protection [...]
2025-03-07
Wegovy's price cut, Amgen's Ozempic competitor, and Big Pharma's tax cut: Pharma news roundup
Novo Nordisk just cut the price of its weight-loss drug, Wegovy, by more than half for patients who pay without insurance. Amgen (AMGN) announced this week that it has begun two late-stage clinical tr [...]
